{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:00:17Z","timestamp":1785546017669,"version":"3.56.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Transl. Res."],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, yet current therapies\u2014including drugs and catheter ablation\u2014remain suboptimal. Gene therapy offers a promising way to modulate AF\u2019s molecular drivers. This review summarizes recent preclinical studies using viral and non-viral vectors, atrial-specific delivery strategies, and key targets such as ion channels, fibrosis, and oxidative stress. Despite promising results, no AF gene therapy has FDA approval, due to challenges in atrial targeting, immune control, and durable expression. Closing this translational gap is critical for future AF gene therapy.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>Gene therapy for atrial fibrillation leverages viral and non-viral vectors to address targets including fibrosis, ion channels, and oxidative stress.<\/jats:p>","DOI":"10.1007\/s12265-025-10685-0","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:48:46Z","timestamp":1760456926000},"page":"1503-1510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Gene Therapies in Atrial Fibrillation"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5143-2934","authenticated-orcid":false,"given":"Cian","family":"O\u2019Donnell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksei","family":"Mikhailov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asish","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0725-4332","authenticated-orcid":false,"given":"Rishi","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"25","key":"10685_CR1","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019. J Am Coll Cardiol. 2020;76(25):2982\u20133021. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.010.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10685_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-022-00347-9","volume":"8","author":"BJJM Brundel","year":"2022","unstructured":"Brundel BJJM, Ai X, Hills MT, Kuipers MF, Lip GYH, de Groot NMS. Atrial fibrillation. Nat Rev Dis Primers. 2022;8(1):1\u201323. https:\/\/doi.org\/10.1038\/s41572-022-00347-9.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10685_CR3","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41569-022-00820-8","volume":"20","author":"AD Elliott","year":"2023","unstructured":"Elliott AD, Middeldorp ME, Van Gelder IC, Albert CM, Sanders P. Epidemiology and modifiable risk factors for atrial fibrillation. Nat Rev Cardiol. 2023;20(6):404\u201317. https:\/\/doi.org\/10.1038\/s41569-022-00820-8.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10685_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/gt.2010.105","volume":"18","author":"K-MR Prasad","year":"2011","unstructured":"Prasad K-MR, Xu Y, Yang Z, Acton ST, French BA. Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a poisson distribution. Gene Ther. 2011;18(1):43\u201352. https:\/\/doi.org\/10.1038\/gt.2010.105.","journal-title":"Gene Ther"},{"issue":"21","key":"10685_CR5","doi-asserted-by":"publisher","first-page":"18979","DOI":"10.1074\/jbc.M201257200","volume":"277","author":"R Aikawa","year":"2002","unstructured":"Aikawa R, Huggins GS, Snyder RO. Cardiomyocyte-specific gene expression following recombinant adeno-associated viral vector transduction. J Biol Chem. 2002;277(21):18979\u201385. https:\/\/doi.org\/10.1074\/jbc.M201257200.","journal-title":"J Biol Chem"},{"issue":"2","key":"10685_CR6","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1161\/CIRCRESAHA.118.313811","volume":"124","author":"L Ni","year":"2019","unstructured":"Ni L, et al. Atrial-specific gene delivery using an adeno-associated viral vector. Circ Res. 2019;124(2):256\u201362. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.313811.","journal-title":"Circ Res"},{"issue":"6669","key":"10685_CR7","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806\u201311. https:\/\/doi.org\/10.1038\/35888.","journal-title":"Nature"},{"key":"10685_CR8","doi-asserted-by":"publisher","DOI":"10.21037\/cdt-24-164","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zhang R, Wang X, Fang S, Wang B. Role of STK38L in atrial fibrillation-associated myocardial fibrosis: findings from RNA-seq analysis. Cardiovasc Diagn Ther. 2024. https:\/\/doi.org\/10.21037\/cdt-24-164.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"9","key":"10685_CR9","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.addr.2009.04.004","volume":"61","author":"DD Rao","year":"2009","unstructured":"Rao DD, Vorhies JS, Senzer N, Nemunaitis J. SiRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev. 2009;61(9):746\u201359. https:\/\/doi.org\/10.1016\/j.addr.2009.04.004.","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"10685_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/biom14091053","volume":"14","author":"Y Yuan","year":"2024","unstructured":"Yuan Y, et al. BMP2 diminishes angiotensin II-induced atrial fibrillation by inhibiting NLRP3 inflammasome signaling in atrial fibroblasts. Biomolecules. 2024;14(9): 1053. https:\/\/doi.org\/10.3390\/biom14091053.","journal-title":"Biomolecules"},{"issue":"4","key":"10685_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12040811","volume":"12","author":"EP Vardas","year":"2024","unstructured":"Vardas EP, Theofilis P, Oikonomou E, Vardas PE, Tousoulis D. Micrornas in atrial fibrillation: mechanisms, vascular implications, and therapeutic potential. Biomedicines. 2024;12(4): 811. https:\/\/doi.org\/10.3390\/biomedicines12040811.","journal-title":"Biomedicines"},{"key":"10685_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1056134","volume":"10","author":"K Pradhan","year":"2023","unstructured":"Pradhan K, et al. Microrna-21 mediated cross-talk between cardiomyocytes and fibroblasts in patients with atrial fibrillation. Front Cardiovasc Med. 2023;10: 1056134. https:\/\/doi.org\/10.3389\/fcvm.2023.1056134.","journal-title":"Front Cardiovasc Med"},{"key":"10685_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.omtn.2023.07.018","volume":"33","author":"IJ Corydon","year":"2023","unstructured":"Corydon IJ, et al. 25 years of maturation: a systematic review of RNAi in the clinic. Mol Ther. 2023;33:469\u201382. https:\/\/doi.org\/10.1016\/j.omtn.2023.07.018.","journal-title":"Mol Ther"},{"issue":"6","key":"10685_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9062004","volume":"9","author":"K Dhuri","year":"2020","unstructured":"Dhuri K, et al. Antisense oligonucleotides: an emerging area in drug discovery and development. J Clin Med. 2020;9(6): 2004. https:\/\/doi.org\/10.3390\/jcm9062004.","journal-title":"J Clin Med"},{"key":"10685_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.yjmcc.2020.07.011","volume":"147","author":"A Saljic","year":"2020","unstructured":"Saljic A, Soattin L, Trachsel DS, Boddum K, Jespersen T. In vivo knockdown of SK3 channels using antisense oligonucleotides protects against atrial fibrillation in rats. J Mol Cell Cardiol. 2020;147:18\u201326. https:\/\/doi.org\/10.1016\/j.yjmcc.2020.07.011.","journal-title":"J Mol Cell Cardiol"},{"issue":"3","key":"10685_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.122.011602","volume":"16","author":"C Schulz","year":"2023","unstructured":"Schulz C, et al. PITX2 knockout induces key findings of electrical remodeling as seen in persistent atrial fibrillation. Circ Arrhythm Electrophysiol. 2023;16(3): e011602. https:\/\/doi.org\/10.1161\/CIRCEP.122.011602.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10685_CR17","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.80317","volume":"12","author":"FM Bosada","year":"2023","unstructured":"Bosada FM, et al. An atrial fibrillation-associated regulatory region modulates cardiac Tbx5 levels and arrhythmia susceptibility. Elife. 2023;12: e80317. https:\/\/doi.org\/10.7554\/eLife.80317.","journal-title":"Elife"},{"issue":"11","key":"10685_CR18","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1016\/j.ymthe.2021.09.002","volume":"29","author":"GA Newby","year":"2021","unstructured":"Newby GA, Liu DR. In vivo somatic cell base editing and prime editing. Mol Ther. 2021;29(11):3107\u201324. https:\/\/doi.org\/10.1016\/j.ymthe.2021.09.002.","journal-title":"Mol Ther"},{"issue":"3","key":"10685_CR19","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.coi.2011.03.008","volume":"23","author":"NY Sardesai","year":"2011","unstructured":"Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol. 2011;23(3):421\u20139. https:\/\/doi.org\/10.1016\/j.coi.2011.03.008.","journal-title":"Curr Opin Immunol"},{"issue":"13","key":"10685_CR20","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1161\/CIRCULATIONAHA.119.044127","volume":"142","author":"S Yoo","year":"2020","unstructured":"Yoo S, et al. Attenuation of oxidative injury with targeted expression of NADPH oxidase 2 short hairpin RNA prevents onset and maintenance of electrical remodeling in the canine atrium. Circulation. 2020;142(13):1261\u201378. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044127.","journal-title":"Circulation"},{"issue":"12","key":"10685_CR21","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.19102\/icrm.2018.091204","volume":"9","author":"A Trivedi","year":"2018","unstructured":"Trivedi A, Arora R. Gene therapy for the treatment of cardiac arrhythmias: current and emerging applications. J Innov Cardiac Rhythm Manage. 2018;9(12):3440\u20135. https:\/\/doi.org\/10.19102\/icrm.2018.091204.","journal-title":"J Innov Cardiac Rhythm Manage"},{"issue":"45","key":"10685_CR22","doi-asserted-by":"publisher","first-page":"26777","DOI":"10.1039\/D0RA03491F","volume":"10","author":"Y Duan","year":"2020","unstructured":"Duan Y, et al. A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems. RSC Adv. 2020;10(45):26777\u201391. https:\/\/doi.org\/10.1039\/D0RA03491F.","journal-title":"RSC Adv"},{"issue":"1","key":"10685_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1716153.","journal-title":"N Engl J Med"},{"issue":"1","key":"10685_CR24","doi-asserted-by":"publisher","first-page":"C107","DOI":"10.1152\/ajpcell.00504.2023","volume":"326","author":"B Jardin","year":"2024","unstructured":"Jardin B, Epstein JA. Emerging mRNA therapies for cardiac fibrosis. Am J Physiol Cell Physiol. 2024;326(1):C107\u201311. https:\/\/doi.org\/10.1152\/ajpcell.00504.2023.","journal-title":"Am J Physiol Cell Physiol"},{"key":"10685_CR25","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.2147\/IJN.S366962","volume":"17","author":"S Scalzo","year":"2022","unstructured":"Scalzo S, et al. Ionizable Lipid Nanoparticle-Mediated Delivery of Plasmid DNA in Cardiomyocytes. Int J Nanomedicine. Jun.2022;17:2865\u201381. https:\/\/doi.org\/10.2147\/IJN.S366962.","journal-title":"Int J Nanomedicine"},{"issue":"6","key":"10685_CR26","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41569-020-00499-9","volume":"18","author":"S Sahoo","year":"2021","unstructured":"Sahoo S, Kariya T, Ishikawa K. Targeted delivery of therapeutic agents to the heart. Nat Rev Cardiol. 2021;18(6):389\u201399. https:\/\/doi.org\/10.1038\/s41569-020-00499-9.","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"10685_CR27","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.ymthe.2018.04.024","volume":"26","author":"M Adamiak","year":"2018","unstructured":"Adamiak M, Sahoo S. Exosomes in myocardial repair: advances and challenges in the development of next-generation therapeutics. Mol Ther. 2018;26(7):1635\u201343. https:\/\/doi.org\/10.1016\/j.ymthe.2018.04.024.","journal-title":"Mol Ther"},{"issue":"1","key":"10685_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03617-y","volume":"20","author":"H Hao","year":"2022","unstructured":"Hao H, et al. Atrial myocyte-derived exosomal microRNA contributes to atrial fibrosis in atrial fibrillation. J Transl Med. 2022;20(1): 407. https:\/\/doi.org\/10.1186\/s12967-022-03617-y.","journal-title":"J Transl Med"},{"key":"10685_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.712828","author":"S Huang","year":"2021","unstructured":"Huang S, Deng Y, Xu J, Liu J, Liu L, Fan C. The role of exosomes and their cargos in the mechanism, diagnosis, and treatment of atrial fibrillation. Front Cardiovasc Med. 2021. https:\/\/doi.org\/10.3389\/fcvm.2021.712828.","journal-title":"Front Cardiovasc Med"},{"issue":"25","key":"10685_CR30","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1161\/CIRCULATIONAHA.120.052009","volume":"143","author":"O Shaihov-Teper","year":"2021","unstructured":"Shaihov-Teper O, et al. Extracellular vesicles from epicardial fat facilitate atrial fibrillation. Circulation. 2021;143(25):2475\u201393. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052009.","journal-title":"Circulation"},{"issue":"1","key":"10685_CR31","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.1080\/21691401.2019.1671432","volume":"47","author":"L Liu","year":"2019","unstructured":"Liu L, Zhang H, Mao H, Li X, Hu Y. Exosomal miR-320d derived from adipose tissue-derived MSCs inhibits apoptosis in cardiomyocytes with atrial fibrillation (AF). Artif Cells Nanomed Nanobiotechnol. 2019;47(1):3976\u201384. https:\/\/doi.org\/10.1080\/21691401.2019.1671432.","journal-title":"Artif Cells Nanomed Nanobiotechnol"},{"issue":"4","key":"10685_CR32","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00608-7","volume":"23","author":"H Zu","year":"2021","unstructured":"Zu H, Gao D. Non-viral vectors in gene therapy: recent development, challenges, and prospects. AAPS J. 2021;23(4): 78. https:\/\/doi.org\/10.1208\/s12248-021-00608-7.","journal-title":"AAPS J"},{"issue":"1","key":"10685_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02805-w","volume":"22","author":"D Lu","year":"2024","unstructured":"Lu D, Fan X. Insights into the prospects of nanobiomaterials in the treatment of cardiac arrhythmia. J Nanobiotechnology. 2024;22(1): 523. https:\/\/doi.org\/10.1186\/s12951-024-02805-w.","journal-title":"J Nanobiotechnology"},{"key":"10685_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00487-6","volume":"6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6: 53. https:\/\/doi.org\/10.1038\/s41392-021-00487-6.","journal-title":"Signal Transduct Target Ther"},{"key":"10685_CR35","doi-asserted-by":"publisher","unstructured":"Schwartze JT, Havenga M, Wam B, Bradshaw AC, Nicklin SA. Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective. J Mol Med Berl Ger. 2022;100 (6):875\u2013901. https:\/\/doi.org\/10.1007\/s00109-022-02208-0.","DOI":"10.1007\/s00109-022-02208-0"},{"issue":"5","key":"10685_CR36","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.jtcvs.2017.05.052","volume":"154","author":"Z Liu","year":"2017","unstructured":"Liu Z, Hutt JA, Rajeshkumar B, Azuma Y, Duan KL, Donahue JK. Preclinical efficacy and safety of KCNH2-G628S gene therapy for post-operative atrial fibrillation. J Thorac Cardiovasc Surg. 2017;154(5):1644-1651.e8. https:\/\/doi.org\/10.1016\/j.jtcvs.2017.05.052.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"10685_CR37","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/bcpt.13885","volume":"133","author":"JM Benson","year":"2023","unstructured":"Benson JM, et al. Preclinical safety and biodistribution assessment of Ad-KCNH2-G628S administered via atrial painting in New Zealand White rabbits. Basic Clin Pharmacol Toxicol. 2023;133(2):179\u201393. https:\/\/doi.org\/10.1111\/bcpt.13885.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"5","key":"10685_CR38","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18(5):358\u201378. https:\/\/doi.org\/10.1038\/s41573-019-0012-9.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10685_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ymthe.2006.03.014","volume":"14","author":"K Inagaki","year":"2006","unstructured":"Inagaki K, et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther. 2006;14(1):45\u201353. https:\/\/doi.org\/10.1016\/j.ymthe.2006.03.014.","journal-title":"Mol Ther"},{"issue":"6","key":"10685_CR40","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/mt.2011.22","volume":"19","author":"N Pulicherla","year":"2011","unstructured":"Pulicherla N, et al. Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol Ther. 2011;19(6):1070\u20138. https:\/\/doi.org\/10.1038\/mt.2011.22.","journal-title":"Mol Ther"},{"issue":"11","key":"10685_CR41","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","volume":"31","author":"D Duan","year":"2023","unstructured":"Duan D. Lethal immunotoxicity in high-dose systemic AAV therapy. Mol Ther. 2023;31(11):3123\u20136. https:\/\/doi.org\/10.1016\/j.ymthe.2023.10.015.","journal-title":"Mol Ther"},{"issue":"6","key":"10685_CR42","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.fmre.2022.05.002","volume":"2","author":"H Hu","year":"2022","unstructured":"Hu H, et al. Long-term amelioration of an early-onset familial atrial fibrillation model with AAV-mediated in vivo gene therapy. Fundam Res. 2022;2(6):829\u201335. https:\/\/doi.org\/10.1016\/j.fmre.2022.05.002.","journal-title":"Fundam Res"},{"issue":"5","key":"10685_CR43","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s00395-002-0360-0","volume":"97","author":"J Zhao","year":"2002","unstructured":"Zhao J, et al. Lentiviral vectors for delivery of genes into neonatal and adult ventricular cardiac myocytes in vitro and in vivo. Basic Res Cardiol. 2002;97(5):348\u201358. https:\/\/doi.org\/10.1007\/s00395-002-0360-0.","journal-title":"Basic Res Cardiol"},{"issue":"4","key":"10685_CR44","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2021.12380","volume":"24","author":"J Zhu","year":"2021","unstructured":"Zhu J, Zhu N, Xu J. MiR-101a-3p overexpression prevents acetylcholine-CaCl2-induced atrial fibrillation in rats via reduction of atrial tissue fibrosis, involving inhibition of EZH2. Mol Med Rep. 2021;24(4): 740. https:\/\/doi.org\/10.3892\/mmr.2021.12380.","journal-title":"Mol Med Rep"},{"issue":"4","key":"10685_CR45","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1007\/s11033-020-05347-0","volume":"47","author":"L Yao","year":"2020","unstructured":"Yao L, Zhou B, You L, Hu H, Xie R. LncRNA MIAT\/miR-133a-3p axis regulates atrial fibrillation and atrial fibrillation-induced myocardial fibrosis. Mol Biol Rep. 2020;47(4):2605\u201317. https:\/\/doi.org\/10.1007\/s11033-020-05347-0.","journal-title":"Mol Biol Rep"},{"issue":"8","key":"10685_CR46","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1177\/01926233241298892","volume":"52","author":"BT Assaf","year":"2024","unstructured":"Assaf BT. Systemic toxicity of recombinant adeno-associated virus gene therapy vectors. Toxicol Pathol. 2024;52(8):523\u201330. https:\/\/doi.org\/10.1177\/01926233241298892.","journal-title":"Toxicol Pathol"},{"issue":"4","key":"10685_CR47","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s12265-010-9190-x","volume":"3","author":"JA Mariani","year":"2010","unstructured":"Mariani JA, Kaye DM. Delivery of gene and cellular therapies for heart disease. J Cardiovasc Transl Res. 2010;3(4):417\u201326. https:\/\/doi.org\/10.1007\/s12265-010-9190-x.","journal-title":"J Cardiovasc Transl Res"},{"issue":"3","key":"10685_CR48","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","volume":"124","author":"M Jessup","year":"2011","unstructured":"Jessup M, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID). Circulation. 2011;124(3):304\u201313. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.022889.","journal-title":"Circulation"},{"issue":"6","key":"10685_CR49","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/gt.2012.11","volume":"19","author":"MG Katz","year":"2012","unstructured":"Katz MG, Fargnoli AS, Pritchette LA, Bridges CR. Gene delivery technologies for cardiac applications. Gene Ther. 2012;19(6):659\u201369. https:\/\/doi.org\/10.1038\/gt.2012.11.","journal-title":"Gene Ther"},{"key":"10685_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54635-x","volume":"15","author":"R Mazurek","year":"2024","unstructured":"Mazurek R, et al. Aav delivery strategy with mechanical support for safe and efficacious cardiac gene transfer in swine. Nat Commun. 2024;15: 10450. https:\/\/doi.org\/10.1038\/s41467-024-54635-x.","journal-title":"Nat Commun"},{"issue":"6","key":"10685_CR51","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S0735-1097(03)00915-X","volume":"42","author":"G von Degenfeld","year":"2003","unstructured":"von Degenfeld G, et al. Selective pressure-regulated retroinfusion of fibroblast growth factor-2 into the coronary vein enhances regional myocardial blood flow and function in pigs with chronic myocardial ischemia. J Am Coll Cardiol. 2003;42(6):1120\u20138. https:\/\/doi.org\/10.1016\/S0735-1097(03)00915-X.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10685_CR52","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1161\/01.CIR.0000153338.47507.83","volume":"111","author":"K Kikuchi","year":"2005","unstructured":"Kikuchi K, McDonald AD, Sasano T, Donahue JK. Targeted modification of atrial electrophysiology by homogeneous transmural atrial gene transfer. Circulation. 2005;111(3):264\u201370. https:\/\/doi.org\/10.1161\/01.CIR.0000153338.47507.83.","journal-title":"Circulation"},{"issue":"21","key":"10685_CR53","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.109.911156","volume":"121","author":"A Guy","year":"2010","unstructured":"Guy A, Kikuchi K, Greener ID, Yang L, Novack V, Donahue JK. Selective molecular potassium channel blockade prevents atrial fibrillation. Circulation. Jun.2010;121(21):2263\u201370. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.911156.","journal-title":"Circulation"},{"issue":"2","key":"10685_CR54","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1161\/CIRCULATIONAHA.111.053272","volume":"125","author":"T Igarashi","year":"2012","unstructured":"Igarashi T, et al. Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation. 2012;125(2):216\u201325. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.053272.","journal-title":"Circulation"},{"issue":"1","key":"10685_CR55","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1161\/CIRCRESAHA.115.307878","volume":"119","author":"A Kunamalla","year":"2016","unstructured":"Kunamalla A, et al. Constitutive expression of a dominant-negative TGF-\u03b2 type II receptor in the posterior left atrium leads to beneficial remodeling of atrial fibrillation substrate. Circ Res. 2016;119(1):69\u201382. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.307878.","journal-title":"Circ Res"},{"issue":"11","key":"10685_CR56","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/j.hrthm.2011.06.018","volume":"8","author":"GL Aistrup","year":"2011","unstructured":"Aistrup GL, et al. Targeted nonviral gene-based inhibition of G\u03b1i\/o-mediated vagal signaling in the posterior left atrium decreases vagal-induced atrial fibrillation. Heart Rhythm. 2011;8(11):1722\u20139. https:\/\/doi.org\/10.1016\/j.hrthm.2011.06.018.","journal-title":"Heart Rhythm"},{"key":"10685_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.889706","volume":"9","author":"G Li","year":"2022","unstructured":"Li G, Yang J, Zhang D, Wang X, Han J, Guo X. Research progress of myocardial fibrosis and atrial fibrillation. Front Cardiovasc Med. 2022;9: 889706. https:\/\/doi.org\/10.3389\/fcvm.2022.889706.","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"10685_CR58","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jacep.2017.03.002","volume":"3","author":"S Nattel","year":"2017","unstructured":"Nattel S. Molecular and cellular mechanisms of atrial fibrosis in atrial fibrillation. JACC Clin Electrophysiol. 2017;3(5):425\u201335. https:\/\/doi.org\/10.1016\/j.jacep.2017.03.002.","journal-title":"JACC Clin Electrophysiol"},{"issue":"3","key":"10685_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122674","volume":"10","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, et al. Microrna profiling of atrial fibrillation in canines: miR-206 modulates intrinsic cardiac autonomic nerve remodeling by regulating SOD1. PLoS One. 2015;10(3): e0122674. https:\/\/doi.org\/10.1371\/journal.pone.0122674.","journal-title":"PLoS One"},{"issue":"2","key":"10685_CR60","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/eurheartj\/ehr269","volume":"34","author":"K Trappe","year":"2013","unstructured":"Trappe K, et al. Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study. Eur Heart J. 2013;34(2):147\u201357. https:\/\/doi.org\/10.1093\/eurheartj\/ehr269.","journal-title":"Eur Heart J"},{"key":"10685_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.862164","volume":"13","author":"K Ihara","year":"2022","unstructured":"Ihara K, Sasano T. Role of inflammation in the pathogenesis of atrial fibrillation. Front Physiol. 2022;13: 862164. https:\/\/doi.org\/10.3389\/fphys.2022.862164.","journal-title":"Front Physiol"},{"issue":"23","key":"10685_CR62","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1016\/j.jacc.2022.03.379","volume":"79","author":"A Ajoolabady","year":"2022","unstructured":"Ajoolabady A, Nattel S, Lip GYH, Ren J. Inflammasome signaling in atrial fibrillation: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79(23):2349\u201366. https:\/\/doi.org\/10.1016\/j.jacc.2022.03.379.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10685_CR63","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1161\/CIRCULATIONAHA.118.035202","volume":"138","author":"C Yao","year":"2018","unstructured":"Yao C, et al. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation. Circulation. 2018;138(20):2227\u201342. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035202.","journal-title":"Circulation"},{"issue":"2","key":"10685_CR64","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/FJC.0b013e31816c4325","volume":"52","author":"JR Ehrlich","year":"2008","unstructured":"Ehrlich JR. Inward rectifier potassium currents as a target for atrial fibrillation therapy. J Cardiovasc Pharmacol. 2008;52(2):129. https:\/\/doi.org\/10.1097\/FJC.0b013e31816c4325.","journal-title":"J Cardiovasc Pharmacol"},{"key":"10685_CR65","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/978-3-642-41588-3_7","volume":"221","author":"C Antzelevitch","year":"2014","unstructured":"Antzelevitch C, Nesterenko V, Shryock JC, Rajamani S, Song Y, Belardinelli L. The role of late INa in development of cardiac arrhythmias. Handb Exp Pharmacol. 2014;221:137\u201368. https:\/\/doi.org\/10.1007\/978-3-642-41588-3_7.","journal-title":"Handb Exp Pharmacol"},{"issue":"6","key":"10685_CR66","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.21037\/jtd-22-534","volume":"14","author":"T Zou","year":"2022","unstructured":"Zou T, et al. Moricizine prevents atrial fibrillation by late sodium current inhibition in atrial myocytes. J Thorac Dis. 2022;14(6):2187\u2013200. https:\/\/doi.org\/10.21037\/jtd-22-534.","journal-title":"J Thorac Dis"},{"issue":"4","key":"10685_CR67","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1161\/CIRCULATIONAHA.104.506857","volume":"112","author":"N Gaborit","year":"2005","unstructured":"Gaborit N, et al. Human atrial ion channel and transporter subunit gene-expression remodeling associated with valvular heart disease and atrial fibrillation. Circulation. 2005;112(4):471\u201381. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.104.506857.","journal-title":"Circulation"},{"issue":"5","key":"10685_CR68","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1161\/01.RES.85.5.428","volume":"85","author":"DR Van Wagoner","year":"1999","unstructured":"Van Wagoner DR, Pond AL, Lamorgese M, Rossie SS, McCarthy PM, Nerbonne JM. Atrial L-type Ca2+ currents and human atrial fibrillation. Circ Res. 1999;85(5):428\u201336. https:\/\/doi.org\/10.1161\/01.RES.85.5.428.","journal-title":"Circ Res"},{"issue":"9","key":"10685_CR69","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s41419-018-0860-y","volume":"9","author":"Y Yuan","year":"2018","unstructured":"Yuan Y, et al. Autophagy exacerbates electrical remodeling in atrial fibrillation by ubiquitin-dependent degradation of L-type calcium channel. Cell Death Dis. 2018;9(9):873. https:\/\/doi.org\/10.1038\/s41419-018-0860-y.","journal-title":"Cell Death Dis"},{"issue":"4","key":"10685_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/biology11040489","volume":"11","author":"Y-H Guo","year":"2022","unstructured":"Guo Y-H, Yang Y-Q. Atrial fibrillation: focus on myocardial connexins and gap junctions. Biology. 2022;11(4): 489. https:\/\/doi.org\/10.3390\/biology11040489.","journal-title":"Biology"},{"issue":"2","key":"10685_CR71","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/cvr\/cvr209","volume":"92","author":"O Bikou","year":"2011","unstructured":"Bikou O, et al. Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc Res. 2011;92(2):218\u201325. https:\/\/doi.org\/10.1093\/cvr\/cvr209.","journal-title":"Cardiovasc Res"},{"key":"10685_CR72","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ijcard.2017.12.050","volume":"255","author":"J Heijman","year":"2018","unstructured":"Heijman J, et al. Muscarinic type-1 receptors regulate IK,ACh in human atrial cardiomyocytes and are upregulated in patients with chronic atrial fibrillation. Int J Cardiol. 2018;255:61\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2017.12.050.","journal-title":"Int J Cardiol"},{"issue":"3","key":"10685_CR73","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/cvr\/cvp148","volume":"83","author":"GL Aistrup","year":"2009","unstructured":"Aistrup GL, et al. Targeted G-protein inhibition as a novel approach to decrease vagal atrial fibrillation by selective parasympathetic attenuation. Cardiovasc Res. 2009;83(3):481\u201392. https:\/\/doi.org\/10.1093\/cvr\/cvp148.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"10685_CR74","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ijcard.2006.04.026","volume":"115","author":"P Korantzopoulos","year":"2007","unstructured":"Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol. 2007;115(2):135\u201343. https:\/\/doi.org\/10.1016\/j.ijcard.2006.04.026.","journal-title":"Int J Cardiol"},{"issue":"2","key":"10685_CR75","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/cvr\/cvp216","volume":"84","author":"A Sridhar","year":"2009","unstructured":"Sridhar A, et al. Chronic heart failure and the substrate for atrial fibrillation. Cardiovasc Res. 2009;84(2):227\u201336. https:\/\/doi.org\/10.1093\/cvr\/cvp216.","journal-title":"Cardiovasc Res"},{"issue":"10","key":"10685_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12101833","volume":"12","author":"R Ramos-Mondrag\u00f3n","year":"2023","unstructured":"Ramos-Mondrag\u00f3n R, Lozhkin A, Vendrov AE, Runge MS, Isom LL, Madamanchi NR. NADPH oxidases and oxidative stress in the pathogenesis of atrial fibrillation. Antioxidants. 2023;12(10): 1833. https:\/\/doi.org\/10.3390\/antiox12101833.","journal-title":"Antioxidants"},{"issue":"1","key":"10685_CR77","doi-asserted-by":"publisher","first-page":"C53","DOI":"10.1152\/ajpcell.2001.280.1.C53","volume":"280","author":"DA Siwik","year":"2001","unstructured":"Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol. 2001;280(1):C53-60. https:\/\/doi.org\/10.1152\/ajpcell.2001.280.1.C53.","journal-title":"Am J Physiol Cell Physiol"},{"key":"10685_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.01380","volume":"9","author":"NC Denham","year":"2018","unstructured":"Denham NC, et al. Calcium in the pathophysiology of atrial fibrillation and heart failure. Front Physiol. 2018;9: 1380. https:\/\/doi.org\/10.3389\/fphys.2018.01380.","journal-title":"Front Physiol"},{"key":"10685_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1327387","author":"B Vandenberk","year":"2024","unstructured":"Vandenberk B, Haemers P, Morillo C. The autonomic nervous system in atrial fibrillation\u2014pathophysiology and non-invasive assessment. Front Cardiovasc Med. 2024. https:\/\/doi.org\/10.3389\/fcvm.2023.1327387.","journal-title":"Front Cardiovasc Med"},{"issue":"10","key":"10685_CR80","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1161\/CIRCRESAHA.111.243972","volume":"110","author":"B Lass\u00e8gue","year":"2012","unstructured":"Lass\u00e8gue B, San Mart\u00edn A, Griendling KK. Biochemistry, physiology and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res. 2012;110(10):1364\u201390. https:\/\/doi.org\/10.1161\/CIRCRESAHA.111.243972.","journal-title":"Circ Res"},{"issue":"8","key":"10685_CR81","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1161\/01.RES.0000218989.52072.e7","volume":"98","author":"C Zhou","year":"2006","unstructured":"Zhou C, Ziegler C, Birder LA, Stewart AFR, Levitan ES. Angiotensin II and stretch activate NADPH oxidase to destabilize cardiac Kv4.3 channel mRNA. Circ Res. 2006;98(8):1040\u20137. https:\/\/doi.org\/10.1161\/01.RES.0000218989.52072.e7.","journal-title":"Circ Res"},{"issue":"Pt 3","key":"10685_CR82","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1042\/BJ20020228","volume":"364","author":"A Hudmon","year":"2002","unstructured":"Hudmon A, Schulman H. Structure-function of the multifunctional Ca2+\/calmodulin-dependent protein kinase II. Biochem J. 2002;364(Pt 3):593\u2013611. https:\/\/doi.org\/10.1042\/BJ20020228.","journal-title":"Biochem J"},{"issue":"21","key":"10685_CR83","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120728","volume":"3","author":"S Yoo","year":"2018","unstructured":"Yoo S, et al. Oxidative stress creates a unique, CaMKII-mediated substrate for atrial fibrillation in heart failure. JCI Insight. 2018;3(21): e120728. https:\/\/doi.org\/10.1172\/jci.insight.120728.","journal-title":"JCI Insight"},{"issue":"7","key":"10685_CR84","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.hrthm.2019.01.013","volume":"16","author":"Z Liu","year":"2019","unstructured":"Liu Z, Finet JE, Wolfram JA, Anderson ME, Ai X, Donahue JK. Calcium\/calmodulin-dependent protein kinase II causes atrial structural remodeling associated with atrial fibrillation and heart failure. Heart Rhythm. 2019;16(7):1080\u20138. https:\/\/doi.org\/10.1016\/j.hrthm.2019.01.013.","journal-title":"Heart Rhythm"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-025-10685-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-025-10685-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-025-10685-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T14:20:15Z","timestamp":1765549215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-025-10685-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10685"],"URL":"https:\/\/doi.org\/10.1007\/s12265-025-10685-0","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rishi Arora has an ownership interest in Inomagen Therapeutics. The other authors declare no conflicts.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}